A 32-year-old man with newly diagnosed HIV-1 infection (CD4 count 350 cells/μL, viral load 150,000 copies/mL) and no prior antiretroviral therapy presents for initiation of combination antiretroviral therapy. He has normal renal and hepatic function and no comorbidities. According to current WHO and Indian guidelines, what is the preferred first-line integrase inhibitor-based regimen?

Explanation

## First-Line Integrase Inhibitor-Based Regimen **Key Point:** Dolutegravir (DTG) + Tenofovir disoproxil fumarate (TDF) + Lamivudine (3TC) is the WHO-recommended and Indian guideline-preferred first-line regimen for treatment-naïve adults with HIV-1 infection. ### Why Dolutegravir is Preferred **High-Yield:** Dolutegravir offers: - Superior barrier to resistance (requires 2 mutations for resistance, vs 1 for NNRTIs) - Rapid viral suppression (faster than EFV-based regimens) - Excellent tolerability with minimal drug interactions - Effective across CD4 count ranges, including advanced immunosuppression (CD4 < 50) - Once-daily dosing (50 mg daily, no food requirement) - Minimal hepatotoxicity compared to protease inhibitors **Clinical Pearl:** DTG is particularly valuable in resource-limited settings because it maintains efficacy even with suboptimal adherence due to its high genetic barrier to resistance. ### Nucleoside Backbone: TDF + 3TC | Component | Advantages | Notes | |-----------|-----------|-------| | **Tenofovir disoproxil fumarate (TDF)** | Potent, once-daily, long history of use | Monitor renal function; may cause mild bone loss | | **Lamivudine (3TC)** | Excellent tolerability, once-daily, low toxicity | HBV co-infection requires continued 3TC or switch to TAF | **Warning:** TDF requires baseline and periodic renal function monitoring; contraindicated if eGFR < 30 mL/min. ### Why Other Options Are Not First-Line **Raltegravir (Option 1):** Requires twice-daily dosing (400 mg BD) and has lower barrier to resistance than DTG; reserved for DTG-resistant cases or special populations. **Elvitegravir (Option 2):** Requires boosting with cobicistat; higher pill burden and more drug interactions; not recommended as first-line in current guidelines. **Bictegravir (Option 3):** Newer integrase inhibitor; not yet standard in Indian guidelines; limited long-term safety data compared to DTG. **Mnemonic:** **DTG-TDF-3TC = "Durable Triple Gem"** — durable suppression, triple-class backbone, gentle tolerability. **High-Yield:** According to 2023 WHO consolidated guidelines and Indian National AIDS Control Organization (NACO) guidelines, DTG-based regimens are now preferred over EFV-based regimens even in resource-limited settings due to superior efficacy, safety, and barrier to resistance.